MedPath

Magnesium

Generic Name
Magnesium
Brand Names
Vitafol-one
Drug Type
Small Molecule
Chemical Formula
H2Mg
CAS Number
7439-95-4
Unique Ingredient Identifier
I38ZP9992A
Background

Magnesium is classified as an alkaline earth metal and has 2 hydration shells. The element can be found in abundance in the hydrosphere and in mineral salts such as dolomite and magnesium carbonate.

Common dietary sources of magnesium include nuts (cashews, peanuts, almonds), beans, bananas, apples, carrots, broccoli, and leafy greens. Magnesium is an important enzyme cofactor and is essential to several metabolic processes. Further, the mineral helps regulate blood pressure and is necessary for RNA, DNA and protein synthesis among several other functions.

Despite the importance of magnesium and its availability via several food sources, an estimated 56 to 68% of adults who live in developed, western countries do not meet the recommended daily intake (RDI) of magnesium. Several factors and common behaviours reduce the availability of magnesium in the diet such as food processing and cooking vegetables (which are normally a rich source of magnesium).

Indication

Healthy levels of magnesium can be achieved through a well balanced diet, but if food sources are insufficient, magnesium supplements can be used to prevent and treat magnesium deficiencies.

In medicine, various magnesium salts may be used in laxative and antacid products. For example, magnesium citrate is available over-the-counter and may be used to manage occasional constipation. Magnesium sulfate may be used on its own or with total parenteral nutrition to treat hypomagnesemia. Magnesium sulfate is also indicated to prevent seizures in pregnant women with pre-eclampsia, and to manage seizures associated with eclampsia.

Associated Conditions
Calcium Deficiency, Magnesium Deficiency, Zinc Deficiency

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm

Phase 1
Completed
Conditions
Parkinsonian Signs in Older Persons
Interventions
Drug: Carbidopa-Levodopa 25/100 mg
First Posted Date
2024-09-19
Last Posted Date
2025-05-21
Lead Sponsor
University of Michigan
Target Recruit Count
5
Registration Number
NCT06587217
Locations
🇺🇸

Domino's Farms, Ann Arbor, Michigan, United States

🇺🇸

University Hospital, Ann Arbor, Michigan, United States

Magnesium Sulfate in Children Undergoing Laparoscopic Appendectomy

Phase 4
Recruiting
Conditions
Complication of Treatment
Opioid Consumption
Multimodal Analgesia
Acute Appendicitis
Interventions
Drug: Normal saline infusion
Drug: Intravenous magnesium sulfate
First Posted Date
2024-08-20
Last Posted Date
2024-11-12
Lead Sponsor
Medical University of Warsaw
Target Recruit Count
188
Registration Number
NCT06563349
Locations
🇵🇱

Uniwersity Clinic Centre of Medical Uniwersity of Warsaw, Warsaw, Poland

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

Phase 3
Recruiting
Conditions
Parkinson Disease
Interventions
Drug: CVN424 75 mg
Drug: CVN424 150 mg
Drug: Placebo
First Posted Date
2024-08-14
Last Posted Date
2025-02-26
Lead Sponsor
Cerevance
Target Recruit Count
330
Registration Number
NCT06553027
Locations
🇺🇸

Horizon Clinical Research Group, Cypress, Texas, United States

🇺🇸

Texas Movement Disorder Specialists, PLLC, Georgetown, Texas, United States

🇺🇸

Gill Neuroscience, Houston, Texas, United States

and more 23 locations

BnH-015B Clinical Trial in Moderate Alzheimer's Disease

Phase 1
Recruiting
Conditions
Alzheimer Disease
Interventions
Drug: BnH-015B 160 mg
Drug: BnH-015B 40 mg (MAD)
Drug: BnH-015B 5 mg
Drug: BnH-015B 10 mg
Drug: BnH-015B 20 mg
Drug: BnH-015B 40 mg (Dietary impact)
Drug: BnH-015B 40 mg
Drug: BnH-015B 80 mg (Part II)
Drug: BnH-015B Placebo (Part II)
Drug: BnH-015B 40 mg (Part II)
Drug: BnH-015B 80 mg
Drug: BnH-015B 80 mg (MAD)
First Posted Date
2024-08-02
Last Posted Date
2025-01-07
Lead Sponsor
BnH Research
Target Recruit Count
92
Registration Number
NCT06535308
Locations
🇰🇷

Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of

Magnesium Sulphate and Lidocaine in Hemodynamic Changes and Cortisol Levels

Phase 1
Completed
Conditions
Intubation Complication
Interventions
Drug: Magnesium Sulfate 20 MG/ML
Drug: saline solution
First Posted Date
2024-07-24
Last Posted Date
2024-07-24
Lead Sponsor
Arsil Radiansyah
Target Recruit Count
30
Registration Number
NCT06516861
Locations
🇮🇩

Adam Malik General Hospital, Medan, Sumatera Utara, Indonesia

Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1

Phase 3
Recruiting
Conditions
Social Anxiety Disorder
Interventions
Drug: 225 mg BNC210
Drug: Placebo
First Posted Date
2024-07-19
Last Posted Date
2025-04-17
Lead Sponsor
Bionomics Limited
Target Recruit Count
332
Registration Number
NCT06510504
Locations
🇺🇸

AFFIRM-1 Study Site, Austin, Texas, United States

Role of IV Calcium to Prevent Diltiazem-related Hypotension

Phase 4
Completed
Conditions
Hypotension Drug-Induced
Atrial Fibrillation
Rapid Ventricular Response
Interventions
Drug: 90 mg of calcium
Drug: 180 mg Calcium
First Posted Date
2024-07-10
Last Posted Date
2024-07-11
Lead Sponsor
Haseki Training and Research Hospital
Target Recruit Count
217
Registration Number
NCT06494007
Locations
🇹🇷

Haseki Training and Research Hospital, Istanbul, Fatih, Turkey

Protocols for Magnesium Sulfate Maintenance Dose in Overweight and Obese Women Diagnosed With Preeclampsia

Phase 1
Not yet recruiting
Conditions
Severe Preeclampsia
Interventions
Drug: maintenance magnesium sulphate1g/h
Drug: maintenance magnesium sulphate2g/h
First Posted Date
2024-07-03
Last Posted Date
2024-07-03
Lead Sponsor
Ain Shams University
Target Recruit Count
100
Registration Number
NCT06486025

To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

Phase 2
Not yet recruiting
Conditions
Type 2 Diabetes
Interventions
Drug: HDM1002 100 mg
Drug: HDM1002 200 mg BID
Drug: HDM1002 200 mg
Drug: HDM1002 400 mg
Drug: HDM1002 50 mg
Drug: Placebo
First Posted Date
2024-07-01
Last Posted Date
2024-07-01
Lead Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Target Recruit Count
318
Registration Number
NCT06481085
Locations
🇨🇳

Jinan Central Hospital, Jinan, China

🇨🇳

The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China

🇨🇳

Suzhou Municipal Hospital, Suzhou, China

and more 28 locations

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

Phase 2
Recruiting
Conditions
Generalized Anxiety Disorder
Interventions
Drug: ITI-1284 20 mg
Drug: Placebo
Drug: ITI-1284 10 mg
First Posted Date
2024-06-28
Last Posted Date
2025-02-20
Lead Sponsor
Intra-Cellular Therapies, Inc.
Target Recruit Count
705
Registration Number
NCT06480383
Locations
🇺🇸

Clinical Site, Bellevue, Washington, United States

🇺🇸

Clinical SIte, DeSoto, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath